Top Medical News
Dupilumab yields rapid, lasting improvement in erythrodermic atopic dermatitis
2 days ago
Treatment with dupilumab helps improve the signs and symptoms of erythrodermic atopic dermatitis, with the improvements occurring as early as the first week and being sustained over time, according to a study. The drug has an acceptable safety profile.
Oral ritlecitinib safe, effective for treatment of active nonsegmental vitiligo
27 Jan 2023
Treatment with oral ritlecitinib improves outcomes in patients with active nonsegmental vitiligo, without any serious adverse events over 48 weeks, results of a study have shown.
Online on par with in-person care for improving outcomes in psoriasis
26 Jan 2023
An online health model appears to be as effective as in-person care for decreasing functional impairment and depressive symptoms in patients with psoriasis, according to a study.
Rituximab confers cardioprotection on pemphigus patients
23 Jan 2023
Treatment with rituximab in patients with pemphigus appears to yield long-term cardiovascular and metabolic protection as compared with conventional immunosuppressants, a study has shown.
Multiple moles, genetic predisposition up risk of second primary melanomas
22 Jan 2023
Individuals with multiple nevi and high genetic predisposition to melanoma appear to have the highest risks of developing second primary melanomas, according to a study.
Lebrikizumab–topical corticosteroid combo improves outcomes in moderate-to-severe AD
Jairia Dela Cruz, 16 Jan 2023
Treatment with lebrikizumab, when combined with low- to mid-potency topical corticosteroid (TCS), helps reduce disease severity in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD), with a safety profile consistent with that reported in previous AD studies, according to the phase III ADhere trial.
Obesity reduces adalimumab potency against hidradenitis suppurativa
14 Jan 2023
Adalimumab for the treatment of hidradenitis suppurativa appears to be less effective in patients with obesity, a study has found.
Special Reports
Product Highlight - Canespro
15 Jun 2022
Bifonazole Anti-Fungal Cream 1% w/w
Product Highlight - RELIZEMA
16 Jun 2021
Furfuryl Palmitate
Expert consensus: Patient profile should guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Improving Medical Practice through Advancement in Clinical Treatment: IMPACT Aesthetics & Suturing Workshop 2018
Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Conference Reports
Skin biomarkers predict AD risk, severity in newborns
Elvira Manzano, 27 Oct 2022
Predicting which newborn will go on to develop atopic dermatitis (AD) and how severe it will be is now feasible, according to the BABY* study.
Ruxolitinib improves repigmentation in vitiligo through 52 weeks
Elaine Soliven, 21 Oct 2022
Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.
Dupilumab reduces itch, improves skin lesions in prurigo nodularis
Elvira Manzano, 20 Oct 2022
Dupilumab improves itch response and skin lesions in patients with prurigo nodularis (PN) inadequately controlled with prior therapies in the LIBERTY-PN PRIME trial.
Lebrikizumab efficacy in atopic dermatitis maintained at 1 year
Roshini Claire Anthony, 12 Oct 2022

Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.

Ligelizumab safe, effective in patients with chronic spontaneous urticaria
Elaine Soliven, 06 Oct 2022
Ligelizumab, a next-generation anti-IgE antibody, is safe and effective in treating patients with H1-antihistamine (H1-AH) refractory chronic spontaneous urticaria (CSU), according to two phase III studies presented at EADV 2022.
Deucravacitinib bestows benefits in Asian patients with plaque psoriasis
Roshini Claire Anthony, 04 Oct 2022

The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.

Rocatinlimab a new treatment option for head and neck AD?
Audrey Abella, 23 Sep 2022
Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.
Product Highlights
CME Modules